Simon Hegele Healthcare Solutions Accelerates Global Growth Through Partnership with Brazil’s MR In Site

Simon Hegele Healthcare Solutions, a highly specialized service partner for original equipment manufacturers (OEMs) of large-scale medical equipment, announces a new partnership through a majority shareholder investment, in MR In Site, one of Brazil’s largest manufacturers of RF shielding and installation services provider of medical imaging equipment. The agreement includes affiliates Brazil Riggers and Columbia Riggers, which specialize in the rigging and assembly of linear accelerator systems. Corresponding (preliminary) contracts have been concluded, closing will take place in the first half of 2023.

Located in São Paulo, MR In Site has deep experience in the electromedical equipment industry and earned a reputation for delivering exceptional service since their founding in 2005.

This partnership builds on Simon Hegele’s existing operations in Latin America and supports the ongoing global expansion of the company.

“Our partnership with MR In Site is a great opportunity to expand our capabilities in the South American market,” says Jim Nestel, CEO of the Americas and Asia Pacific for Simon Hegele Healthcare Solutions. “Not only does this alliance increase Simon Hegele’s capacity in Brazil, it rapidly enhances the variety of services we can bring to our combined customer bases uptilting the Hegele skill set and experience from around the globe.”

Alex Silva, MR In Site CEO and founder, adds “It was critical to us that our future partner shares the same dedication to quality and reliability as we do. At the end of the day, we are providing services that impact our surrounding community. We are glad to have found a partner in Simon Hegele Healthcare Solutions that aligns with our values and we are looking forward to a great partnership.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”